Key Financials Snapshot

TTM · Standalone · ₹ in Cr
Market Cap
₹5 Cr.
Stock P/E
113.8
P/B
0.2
Current Price
₹2
Book Value
₹ 11.9
Face Value
10
52W High
₹6.4
52W Low
₹ 2
Dividend Yield
0%

Natural Biocon (I) Overview

Business

Natural Biocon (India) Ltd. operates in the trading sector. Its core business involves sourcing various goods and commodities from suppliers and selling them to customers, acting as an intermediary in the supply chain. The company aims to add value through efficient procurement, logistics, and distribution. It makes money by purchasing goods at a wholesale price and selling them at a higher price, earning a margin on the traded volumes. While the name includes "Biocon," the company's primary stated business activity is the general trading of various goods and commodities, rather than specialized biotechnology products.

Revenue Mix

Information regarding specific product categories or geographical segments is not publicly detailed without access to the company's annual reports or filings. Typically, a trading company might segment its revenue by different types of goods (e.g., industrial goods, consumer products, agricultural commodities) or by domestic versus international trade. Without this specific breakdown, it's inferred that revenue is generated from the aggregate trading of various unspecified goods and commodities.

Industry

The trading industry in India is highly fragmented and competitive, characterized by low barriers to entry. Competition often comes from numerous small and medium-sized enterprises, as well as larger, established trading houses. Companies in this sector differentiate through pricing, efficiency of supply chain, strong supplier and customer relationships, and specialized market knowledge. Natural Biocon (India) Ltd., being listed on the NSE Emerge platform, suggests it is likely a smaller player aiming to scale up within this competitive landscape, focusing on carving out its niche through operational effectiveness and market penetration.

MOAT

The trading business generally possesses weak moats due to low product differentiation and ease of entry. Natural Biocon (India) Ltd. is unlikely to have strong competitive advantages such as brand equity, network effects, or high switching costs. Potential sources of a sustainable edge, if any, would stem from:

Efficient Sourcing & Logistics: Ability to procure goods at competitive prices and deliver them cost-effectively.

Established Relationships: Strong, long-term relationships with both suppliers and customers.

Market Intelligence: Superior understanding of demand-supply dynamics and pricing trends in specific product categories.

These advantages are often operational and can be imitated over time, making them less durable than structural moats.

Growth Drivers

Key factors that could drive growth for Natural Biocon (India) Ltd. over the next 3-5 years include:

Economic Growth: A growing Indian economy generally leads to increased demand for various goods and commodities, boosting trading volumes.

Expansion of Product Portfolio: Venturing into new product categories or higher-margin goods.

Geographic Expansion: Expanding trading activities into new domestic regions or international markets.

Improved Supply Chain Efficiencies: Optimizing logistics, inventory management, and warehousing to enhance profitability.

Strategic Partnerships: Forming alliances with larger manufacturers or distributors to expand reach and capabilities.

Risks

Commodity Price Volatility: Fluctuations in the prices of goods traded can significantly impact margins and inventory values.

Intense Competition: The highly fragmented nature of the trading industry leads to pricing pressures and can erode profitability.

Supply Chain Disruptions: Issues like logistical bottlenecks, supplier defaults, or geopolitical events can disrupt operations and impact delivery schedules.

Credit Risk: Risk of non-payment or delayed payment from customers, especially in high-volume trading.

Working Capital Management: Trading businesses are highly working capital intensive; inefficient management can lead to liquidity issues.

Regulatory Changes: Changes in trade policies, import/export duties, or taxation could affect profitability and business models.

Management & Ownership

Natural Biocon (India) Ltd. is typically promoted by a founding family or individuals who often retain significant ownership and control, which is common among smaller Indian listed companies. The management team is responsible for day-to-day operations, strategic planning, and risk management within the highly competitive trading environment. Without specific details on individual management profiles or promoter history, a qualitative assessment of management quality beyond basic competency for a listed entity is not possible. The ownership structure generally includes promoter holdings and public shareholding.

Outlook

Natural Biocon (India) Ltd.'s outlook is closely tied to its operational efficiency and market acumen within the highly competitive trading sector. The bull case envisions the company successfully leveraging India's economic growth, expanding its product offerings and geographical reach, and optimizing its supply chain to capture higher trading volumes and sustainable margins. Its ability to forge strong relationships and manage inventory effectively would be key. The bear case highlights the inherent risks of the trading business, including vulnerability to commodity price volatility, intense competition eroding margins, potential credit defaults from counterparties, and operational inefficiencies that could strain working capital. The absence of strong, structural moats means its performance will heavily depend on continuous operational excellence and astute risk management in a dynamic market.

Natural Biocon (I) Share Price

Live · BSE · Inception: 1992
₹ | |
Volume
Price

Key Financials — Profit & Loss

₹ in Cr · Standalone · annual

Natural Biocon (I) Quarterly Results

#(Fig in Cr.) Mar 2024 Jun 2024 Sep 2024 Dec 2024 Mar 2025 Jun 2025 Sep 2025 Dec 2025 Mar 2026 Jun 2026
Net Sales 11 1 5 1 1 2 0 0 1 0
Other Income 0 0 0 0 0 0 0 0 0 0
Total Income 11 1 5 1 1 2 0 0 1 0
Total Expenditure 11 1 5 1 2 2 0 0 1 0
Operating Profit 0 0 0 0 -0 0 -0 -0 -0 -0
Interest 0 0 0 0 0 0 0 0 0 0
Depreciation 0 0 0 0 0 0 0 0 0 0
Exceptional Income / Expenses 0 0 0 0 0 0 0 0 0 0
Profit Before Tax 0 0 0 0 -0 0 -0 -0 -0 -0
Provision for Tax 0 0 0 0 0 0 0 0 0 0
Profit After Tax 0 0 0 0 -0 0 -0 -0 -0 -0
Adjustments 0 0 -0 0 0 0 -0 -0 0 0
Profit After Adjustments 0 0 0 0 -0 0 -0 -0 -0 -0
Adjusted Earnings Per Share 0.1 0.1 0.1 0.1 -0.2 0.1 -0 -0 -0 -0

Natural Biocon (I) Profit & Loss

#(Fig in Cr.) Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 TTM
Net Sales 0 1 0 0 0 0 1 14 8 1
Other Income 0 0 0 0 0 0 0 0 0 0
Total Income 0 1 0 0 0 0 1 14 8 1
Total Expenditure 0 0 0 0 0 0 1 13 8 1
Operating Profit 0 1 0 -0 0 0 0 0 0 0
Interest 0 0 0 0 0 0 0 0 0 0
Depreciation 0 0 0 0 0 0 0 0 0 0
Exceptional Income / Expenses 0 0 0 0 0 0 0 0 0 0
Profit Before Tax 0 1 0 -0 0 0 0 0 0 0
Provision for Tax 0 0 0 0 0 0 0 0 0 0
Profit After Tax 0 1 0 -0 0 0 0 0 0 0
Adjustments 0 0 0 0 0 0 0 0 0 0
Profit After Adjustments 0 1 0 -0 0 0 0 0 0 0
Adjusted Earnings Per Share 0 0 0 0 0 0.1 0.2 0.1 0 0

Natural Biocon (I) Balance Sheet

#(Fig in Cr.) Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025
Shareholder's Funds 11 12 12 12 12 12 12 12 32
Minority's Interest 0 0 0 0 0 0 0 0 0
Borrowings 0 0 0 0 0 0 0 0 0
Other Non-Current Liabilities 0 0 0 0 0 0 0 0 0
Total Current Liabilities 0 0 1 1 0 0 1 4 7
Total Liabilities 12 12 13 13 12 12 14 17 39
Fixed Assets 0 0 0 0 0 0 0 0 0
Other Non-Current Assets 10 10 11 11 11 11 11 10 31
Total Current Assets 1 2 2 2 2 1 2 6 7
Total Assets 12 12 13 13 12 12 14 17 39

Natural Biocon (I) Cash Flow

#(Fig in Cr.) Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025
Opening Cash & Cash Equivalents 0 0 0 0 0 0 0 0 0
Cash Flow from Operating Activities 0 -0 -1 0 0 0 0 -0 1
Cash Flow from Investing Activities 0 0 0 0 0 0 0 0 -21
Cash Flow from Financing Activities -0 -0 1 -0 -0 -0 -0 -0 20
Net Cash Inflow / Outflow 0 -0 -0 0 0 0 0 -0 -0
Closing Cash & Cash Equivalent 0 0 0 0 0 0 0 0 0

Natural Biocon (I) Ratios

# Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025
Earnings Per Share (Rs) 0 0 0 0 0 0.06 0.16 0.13 0.02
CEPS(Rs) 0.07 0.62 0.06 -0.03 0 0.06 0.16 0.13 0.02
DPS(Rs) 0.05 0.05 0.05 0 0 0 0 0 0
Book NAV/Share(Rs) 0 0 0 0 10.54 10.6 10.75 10.89 12.36
Core EBITDA Margin(%) 70.68 95.96 24.95 0 3.23 18.43 19.79 1.67 0.73
EBIT Margin(%) 70.68 95.96 27.09 0 3.23 18.43 19.79 1.67 0.72
Pre Tax Margin(%) 70.68 95.96 26.95 0 2.78 18.24 19.69 1.66 0.71
PAT Margin (%) 49.48 67.19 16.17 0 2.08 13.68 14.28 1.13 0.53
Cash Profit Margin (%) 49.48 67.19 16.17 0 2.08 13.68 14.28 1.13 0.54
ROA(%) 0.66 5.85 0.57 -0.25 0.02 0.53 1.39 1.01 0.16
ROE(%) 0.67 5.99 0.6 -0.26 0.02 0.55 1.48 1.24 0.2
ROCE(%) 0.95 8.56 0.98 -0.25 0.03 0.72 2.02 1.82 0.27
Receivable days 0 357.46 730.85 0 1569.88 382.81 163.04 74.19 230.35
Inventory Days 131.3 19.34 44.92 0 152.85 41.83 141.34 14.53 7.16
Payable days 0 0 0 0 0 28.57 215.6 73.58 235.95
PER(x) 0 0 0 0 0 156.13 29.46 76.08 857.8
Price/Book(x) 0 0 0 0 0 0.85 0.43 0.94 1.2
Dividend Yield(%) 0 0 0 0 0 0 0 0 0
EV/Net Sales(x) 72.49 10.78 27.1 0 88.62 21.26 4.01 0.85 4.61
EV/Core EBITDA(x) 102.56 11.23 100.06 -380.27 2742.36 115.37 20.26 50.79 630.41
Net Sales Growth(%) 0 579.02 -56.95 -100 0 265.24 160.34 978.97 -38.32
EBIT Growth(%) 0 821.86 -87.85 -125.98 113.49 1983.04 179.55 -8.87 -73.25
PAT Growth(%) 0 822.1 -89.64 -143.63 108.68 2296.71 171.77 -14.77 -70.77
EPS Growth(%) 0 0 0 0 108.62 2312.5 172.02 -14.79 -87.11
Debt/Equity(x) 0 0 0.07 0.06 0.03 0.01 0.01 0.01 0.01
Current Ratio(x) 9.99 5.24 1.86 2.59 4.57 3.78 1.67 1.46 1.06
Quick Ratio(x) 9.56 5.11 1.81 2.51 4.43 3.56 0.96 1.42 1.03
Interest Cover(x) 0 0 192.81 -385.78 7.14 98.67 205.48 247.22 68.3
Total Debt/Mcap(x) 0 0 0 0 0 0.02 0.03 0.01 0.01

Growth Rates

Compounded annual
# 1 Year 3 Year 5 Year 10 Year
Sales CAGR -43% — — —
Operating Profit CAGR — — — —
PAT CAGR — — — —
Share Price CAGR -67% -40% -42% —
ROE Average 0% +1% +1% +1%
ROCE Average 0% +1% +1% +2%

Natural Biocon (I) Shareholding Pattern

Latest · Jun 2026
100% held
Promoters 9.36 %
FII 0 %
DII (MF + Insurance) 0 %
Public (retail) 90.64 %
# Mar 2024 Jun 2024 Sep 2024 Dec 2024 Mar 2025 Jun 2025 Sep 2025 Dec 2025 Mar 2026 Jun 2026
Promoter 21.2221.229.369.369.369.369.369.369.369.36
FII 0000000000
DII 0000000000
Public 78.7878.7890.6490.6490.6490.6490.6490.6490.6490.64
Others 0000000000
Total 100100100100100100100100100100

Natural Biocon (I) Peer Comparison

Natural Biocon (I) Quarterly Price

10-year quarterly close · BSE
Show Value Show %

News & Updates

See more…

Natural Biocon (I) Pros & Cons

Pros

  • Stock is trading at 0.2 times its book value
  • Company is almost debt free.

Cons

  • Promoter holding is low: 9.36%.
  • Company has a low return on equity of 1% over the last 3 years.
  • Debtor days have increased from 73.58 to 235.95days.
Want to Start Investing in Top Unlisted Stocks?

Our experts help you choose the right stocks based on performance, risk, and growth potential.

whatsapp